Reviva Pharmaceuticals Holdings (RVPH) Net Cash Flow (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Net Cash Flow of $7.8 million for Q1 2026, up 517.38% sequentially from $1.3 million in Q4 2025, and up 194.68% YoY from $2.6 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Net Cash Flow (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Net Cash Flow for 9 years, with the latest figure at $7.8 million in Q1 2026.
- Quarterly Net Cash Flow rose 194.68% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 352.85% YoY) and the FY2025 annual result came in at $962461.0, up 109.73% from the prior year.
- Net Cash Flow rose to $7.8 million in Q1 2026 per RVPH's latest filing, from $1.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $18.4 million in Q4 2023 and troughed at -$11.4 million in Q1 2024.
- A 5-year average of -$441041.9 and a median of -$619363.0 in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 5474.17% in 2024, then surged 555.23% in 2025.
- Over 5 years, Net Cash Flow stood at -$4.7 million in 2022, then surged by 493.73% to $18.4 million in 2023, then sank by 56.96% to $7.9 million in 2024, then sank by 84.14% to $1.3 million in 2025, then soared by 517.38% to $7.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $7.8 million, $1.3 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.30 Mn |
| Jun 30, 2026 | -2.30 Mn |
| Mar 31, 2026 | 7.75 Mn |
| Mar 31, 2026 | 7.75 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 2.82 Mn |
| Sep 30, 2025 | 2.82 Mn |
| Jun 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | 5.07 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | 7.92 Mn |
| Dec 31, 2024 | 7.92 Mn |
| Sep 30, 2024 | -619,363.00 |
| Sep 30, 2024 | -619,363.00 |
| Jun 30, 2024 | -5.80 Mn |
| Jun 30, 2024 | -5.80 Mn |
| Mar 31, 2024 | -11.39 Mn |
| Mar 31, 2024 | -11.39 Mn |